Neurology

Generic Lyrica: FDA nods to first generic alternatives to Pfizer’s Lyrica The U.S. FDA has approved the first generic substitute of Pfizer’s Lyrica (pregabalin) in its commitment to facilitate the access of high-quality generic medicines at lower prices to patients. Lyrica is the second most selling drug of the Pfizer, whose patent expired on December 30, 2018. Another six-month extension of the patent further delayed the launch of generic versions of the drug. The approval of nine generic versions of the drug, Lyrica, is for the administration in patients struggling with neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibr...